Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin + Metformin in T2D with Inadequate Control
NCT00661362Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2008
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Metformin + Saxagliptin with Metformin + Placebo (2 arms). Primary endpoint: Glycosylated Haemoglobin A1c at 24 weeks. Started Jun 2008; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00661362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661362.